A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

NCT06752746 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycythemia Vera

Interventions

DRUG: 9MW3011

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.